Patients with cancer are at increased risk for both suicidal ideation and completed suicide due to a combination of biological and psychological factors that must be addressed to increase quality of life.,Unique to cancer is that the risk of suicide persists more than 15 years past diagnosis.4

In addition to increased suicide risk, patients with head and neck cancers have higher depression scores than the general population even before a cancer diagnosis, leading to the question whether this subset of patients are struggling with a biological cause in addition to diagnosis-related symptoms.5 Complicating these cases is the well-known association of many head and neck cancers with tobacco, alcohol, and other substance use, leading to the question of whether the pre-existing mood disorders lead to substance use that increases the risk of cancer.,Depression is a major risk factor, as it is in the general population, but the cancer population is at higher baseline risk for depression, which has been linked to immunological changes.12 Identification and treatment of depression in cancer patients has been shown to decrease morbidity and mortality.13 read more

A paper published in the journal Nature Communications, reveals a potential revolutionary drug combination that -- in animal studies and in world-first 3D models of the tumour -- is "spectacularly effective in eradicating the cancer cells," according to lead researcher and paediatric oncologist Associate Professor c from the Children's Cancer Institute and Sydney Children's Hospital.,These models have been used to show that DIPG can bypass the activity of DFMO by pumping polyamines into cancer, essentially allowing the tumour to continue growing despite treatment with DFMO.,They have now made the breakthrough discovery that treatment with a new developmental drug, AMXT 1501, potently blocks the transport of polyamines into the DIPG cancer cell.,Treatment with AMXT 1501 was found to re-sensitize the DIPG cells to DFMO leading to what Associate Professor Ziegler said, "was a spectacular response in animal models, with a significantly increased survival and minimal toxicity (side effects).",Associate Professor Ziegler said that clinical trials of the drug combination in DIPG are planned to begin this year in children in a global study led by the Children's Cancer Institute and the Kid's Cancer Centre at Sydney Children's Hospital.

A paper published today 12 Feb 2021 in the prestigious journal, Nature Communications, reveals a potential revolutionary drug combination that - in animal studies and in world-first 3D models of the tumor - is "spectacularly effective in eradicating the cancer cells," according to lead researcher and pediatric oncologist Associate Professor David Ziegler, from the Children's Cancer Institute and Sydney Children's Hospital.,These models have been used to show that DIPG can bypass the activity of DFMO by pumping polyamines into cancer, essentially allowing the tumor to continue growing despite treatment with DFMO.,They have now made the breakthrough discovery that treatment with a new developmental drug, AMXT 1501, potently blocks the transport of polyamines into the DIPG cancer cell.,Treatment with AMXT 1501 was found to re-sensitize the DIPG cells to DFMO leading to what Associate Professor Ziegler said, "was a spectacular response in animal models, with a significantly increased survival and minimal toxicity (side effects)".,Associate Professor Ziegler said that clinical trials of the drug combination in DIPG are planned to begin this year in children in a global study led by the Children's Cancer Institute and the Kid's Cancer Centre at Sydney Children's Hospital.

A paper published in the journal Nature Communications, reveals a potential revolutionary drug combination that -- in animal studies and in world-first 3D models of the tumour -- is "spectacularly effective in eradicating the cancer cells," according to lead researcher and paediatric oncologist Associate Professor c from the Children's Cancer Institute and Sydney Children's Hospital.,These models have been used to show that DIPG can bypass the activity of DFMO by pumping polyamines into cancer, essentially allowing the tumour to continue growing despite treatment with DFMO.,They have now made the breakthrough discovery that treatment with a new developmental drug, AMXT 1501, potently blocks the transport of polyamines into the DIPG cancer cell.,Treatment with AMXT 1501 was found to re-sensitize the DIPG cells to DFMO leading to what Associate Professor Ziegler said, "was a spectacular response in animal models, with a significantly increased survival and minimal toxicity (side effects).",Associate Professor Ziegler said that clinical trials of the drug combination in DIPG are planned to begin this year in children in a global study led by the Children's Cancer Institute and the Kid's Cancer Centre at Sydney Children's Hospital.